The cancer cell secretome: a good source for discovering biomarkers?
Cancer is a leading cause of death. Early detection is usually associated with better clinical outcomes. Recent advances in genomics and proteomics raised hopes that new biomarkers for diagnosis, prognosis or monitoring therapeutic response will soon be discovered. Proteins secreted by cancer cells, referred also as "the cancer cell secretome", is a promising source for biomarker discovery. In this review we will summarize recent advances in cancer cell secretome analysis, focusing on the five most fatal cancers (lung, breast, prostate, colorectal, and pancreatic). For each cancer type we will describe the proteomic approaches utilized for the identification of novel biomarkers. Despite progress, identification of markers that are superior to those currently used has proven to be a difficult task and very few, if any, newly discovered biomarker has entered the clinic the last 10 years.
Pavlou
Maria P
MP
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
Diamandis
Eleftherios P
EP
D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000175:diagnosis; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000175:diagnosis; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D014408:Biomarkers, Tumor